Collaboration and License Agreements (Details) $ in Millions	12 Months Ended
Dec. 31, 2020 USD ($)
Collaboration and License Agreements [Abstract]
Ipsen Revenue Recognized	$ 0.3
Ipsen product sales	$ 1.3

In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.

No definition available.

Name:	lxrx_IpsenRevenueRecognized
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration